Claims

What was said, typed and attributed. Statements as reported by the cited publishers — not verified by DecisionGateway.

Follow via RSS — the 30 newest claims in any reader, no account needed.

Claims by
predictionAlthough divesting Frontage may affect some global synergies in the short term, the transaction can improve Tigermed's business portfolio and capital allocation while supporting further expansion of overseas clinical CRO business, supplementing working capital and raising shareholder returns.瑞銀statementTigermed plans to use about 60% of net cash proceeds for overseas clinical CRO expansion and M&A, 20% for daily operations, and the remaining about 20% possibly for dividends or share buybacks.瑞銀predictionIf the transaction completes, Tigermed can divest non-core businesses including overseas laboratories, CMC and genomics to focus more on clinical CRO services.瑞銀statementFrontage's laboratory network in the US and Europe is an important platform linking Tigermed to global markets; it supports the strategy of dual IND filings in China and the US and helps Chinese innovative drugmakers expand overseas, so divesting Frontage may affect Tigermed's global footprint and cross-border drug R&D competitiveness to some extent.瑞銀statementAfter the privatization, Tigermed plans to acquire Frontage's mainland China non-target businesses at a preliminary valuation of about US$205.5 million; target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; founder Li Song and related trusts may acquire the overseas non-target businesses at a preliminary valuation of about US$84.4 million.瑞銀statementThe cancellation price per Frontage Holdings share is HK$2.37, a 107.2% premium to the 360-day average share price, equivalent to about 91.6 times Frontage's 2025 price-to-earnings ratio.瑞銀statementTigermed announced it will participate in the privatization and business split of Frontage Holdings (01521) through its wholly-owned subsidiary Hong Kong Tigermed.瑞銀commitmentUBS maintains a target price of HK$52.6 and a "Buy" rating on Tigermed (03347).瑞銀commitmentTigermed also plans to use about 60% of net cash proceeds for overseas clinical CRO expansion and M&A, 20% for daily operations, and the remaining about 20% may be used for dividends or share buybacks.瑞銀predictionIf the transaction is completed, Tigermed can also divest non-core businesses, including overseas laboratories, CMC and genomics, to focus more on clinical CRO services.瑞銀predictionDivesting Frontage may to some extent affect Tigermed's global layout and cross-border drug R&D competitiveness.瑞銀statementFrontage Holdings' laboratory network in the US and Europe is an important platform linking Tigermed to global markets; it supports the strategy of dual IND submissions in China and the US and helps Chinese innovative drugmakers expand into overseas markets.瑞銀statementAfter the privatization is completed, Tigermed plans to acquire Frontage's non-target business in mainland China at a preliminary valuation of about US$205.5 million; the target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; Frontage founder Li Song and related trusts may acquire the overseas non-target business at a preliminary valuation of about US$84.4 million.瑞銀statementThe cancellation price for each Frontage Holdings share is HK$2.37, a 107.2% premium to the average share price over the past 360 days, equivalent to about 91.6 times Frontage's 2025 price-to-earnings ratio.瑞銀statementTigermed announced it will participate in the privatization and business split of Frontage Holdings through its wholly-owned subsidiary Hong Kong Tigermed.瑞銀commitmentUBS maintains a target price of HK$52.6 and a "Buy" rating for Tigermed (03347).瑞銀statement瑞銀表示,考慮到領展過往在併購方面的表現參差不齊,投資者或許會質疑此次收購及未來潛在的收購能否真正創造可持續的股東價值。瑞銀statement領展先前已動用了14億港元的資產處置所得,這些資金源自出售彌敦道700號(交易額23億港元)以及出售Market Street 100號50%的股權(交易額2.26億澳元)。瑞銀prediction鑑於DPU增值幅度有限,瑞銀預期市場對股價的反應將基本持平。瑞銀prediction瑞銀預期該交易將對每個基金單位分派(DPU)產生約0.5%的溫和增值效應。瑞銀

20 of 30